Which cell therapy startups secured investment?

This blog post has been written by the person who has mapped the cell therapy market in a clean and beautiful presentation

Cell therapy startups secured over $1.3 billion in disclosed funding between 2024 and mid-2025, with ArsenalBio leading at $325 million.

This funding surge represents a maturation phase where investors prioritize clinical-stage programs and scalable platform technologies. The largest rounds went to companies developing breakthrough approaches like in vivo CAR-T delivery and programmable cell therapies for solid tumors.

And if you need to understand this market in 30 minutes with the latest information, you can download our quick market pitch.

Which cell therapy startups secured the largest funding rounds in 2024-2025?

ArsenalBio topped the funding charts with a $325 million Series C round in September 2024, making it one of the largest biotech financings of the year.

Capstan Therapeutics followed with $175 million in Series B funding in March 2024, led by RA Capital Management with participation from major pharma companies including Johnson & Johnson Innovation, Pfizer, Bristol Myers Squibb, Eli Lilly, and Bayer. This oversubscribed round validates the commercial potential of in vivo CAR-T delivery technology.

Neurona Therapeutics raised $102 million in April 2025 from high-profile investors including Fidelity, The Column Group, Soleus Capital, Viking Global, and Cormorant Asset Management. The funding supports their Phase 3 EPIC trial for drug-resistant epilepsy treatment using allogeneic interneuron transplants.

Umoja Biopharma secured $100 million in Q1 2025 led by Double Point Ventures and DCVC Bio to advance their off-the-shelf CAR-T and in vivo engineered T cell platforms. Be Biopharma raised $92 million from ARCH Venture, Atlas Venture, RA Capital, Bristol Myers Squibb Ventures, and Takeda Ventures for B-cell therapies targeting hemophilia and hypophosphatasia.

Rhygaze completed an $86 million Series A round with backing from Google Ventures, Arch Venture, F-Prime, BioGeneration, and Novartis Venture Fund for their optogenetic vision restoration technology.

Who are the most active investors in cell therapy startups and which companies did they fund?

ARCH Venture Partners emerged as the most active strategic investor, backing both ArsenalBio's $325 million round and Be Biopharma's $92 million financing.

RA Capital Management led Capstan Therapeutics' $175 million Series B and participated in multiple other rounds, demonstrating strong conviction in the cell therapy sector. Bristol Myers Squibb Ventures appeared in both ArsenalBio and Be Biopharma deals, signaling Big Pharma's strategic interest in next-generation cell therapies.

Corporate venture arms dominated the landscape with Johnson & Johnson Innovation backing Capstan, Regeneron Ventures co-leading ArsenalBio's round, and Novartis Venture Fund participating in Rhygaze. SoftBank Vision Fund 2 made a notable entry into cell therapy through ArsenalBio's financing, bringing tech sector investment discipline to biotech.

Double Point Ventures and DCVC Bio jointly led Umoja Biopharma's $100 million round, while specialized healthcare investors like The Column Group participated in both Neurona Therapeutics and A2 Biotherapeutics financings. Google Ventures' investment in Rhygaze represents Big Tech's growing interest in healthcare applications.

Looking for the latest market trends? We break them down in sharp, digestible presentations you can skim or share.

If you want fresh and clear data on this market, you can download our latest market pitch deck here

What breakthrough technologies are these investments financing?

ArsenalBio's $325 million funding advances their CITE (Cellular Immunotherapy Technologies & Engineering) platform, which integrates programmable logic gates into CAR-T cells for enhanced specificity against solid tumors.

Capstan Therapeutics uses their funding to develop targeted lipid nanoparticles (tLNPs) that deliver CAR constructs directly into patients' T cells in vivo, eliminating the need for complex ex vivo manufacturing. This approach could dramatically reduce treatment costs and expand patient access.

Neurona Therapeutics focuses on GABAergic interneuron transplantation for drug-resistant epilepsy, representing the first CNS-resident cell therapy in Phase 3 trials. Their RMAT (Regenerative Medicine Advanced Therapy) designation provides an accelerated regulatory pathway.

Umoja Biopharma develops universal donor CAR-T cells and in vivo gene-engineered T cell platforms that bypass patient-specific manufacturing constraints. A2 Biotherapeutics advances their Tmod (targeted modulation) dual-receptor system designed to differentiate cancer cells from healthy tissue, reducing on-target off-tumor toxicity.

Rhygaze pioneers optogenetic vision restoration technology, while Be Biopharma engineers B-cell therapies for rare diseases like hemophilia A and hypophosphatasia, expanding cell therapy applications beyond oncology.

Which regions concentrate the highest number of funded cell therapy startups?

The United States dominates cell therapy funding with the majority of large rounds concentrated in biotech hubs like Boston, San Francisco, and San Diego.

What specific cell therapy approaches are attracting the most investment?

Programmable CAR-T therapies for solid tumors received the largest single investment through ArsenalBio's $325 million round, reflecting investor confidence in overcoming traditional CAR-T limitations.

In vivo cell reprogramming technologies attracted significant capital through Capstan's $175 million financing, as investors recognize the potential to eliminate manufacturing bottlenecks that plague current CAR-T therapies. Allogeneic (off-the-shelf) platforms drew substantial funding through Umoja's $100 million round and Neurona's $102 million financing.

Neurological applications emerged as a high-investment area with Neurona's epilepsy treatment and Rhygaze's vision restoration technology receiving major backing. Dual-receptor platforms like A2 Biotherapeutics' Tmod system address safety concerns that have limited cell therapy expansion into solid tumors.

B-cell engineering platforms through Be Biopharma's $92 million round demonstrate investor interest in expanding beyond T-cell therapies. Platform technologies that enable multiple therapeutic applications, rather than single-indication approaches, consistently attract larger investment rounds.

Manufacturing and scalability solutions embedded within these platforms represent a critical investment theme, as investors prioritize companies that can address cost-of-goods-sold challenges facing the broader cell therapy industry.

Are pharmaceutical giants directly involved in these funding rounds?

Major pharmaceutical companies participated extensively through their corporate venture arms, with Johnson & Johnson Innovation, Bristol Myers Squibb Ventures, Regeneron Ventures, and Novartis Venture Fund leading significant investments.

Bristol Myers Squibb Ventures invested in both ArsenalBio and Be Biopharma, leveraging their CAR-T expertise from Breyanzi and Abecma products. Johnson & Johnson Innovation backed Capstan Therapeutics, aligning with their broader cell therapy strategy through their Janssen division.

Regeneron Ventures co-led ArsenalBio's $325 million round alongside ARCH Venture Partners, bringing oncology drug development expertise to the solid tumor CAR-T challenge. Eli Lilly, Bayer, and Pfizer participated in Capstan's $175 million Series B, indicating broad pharma interest in manufacturing innovations.

Takeda Ventures joined Be Biopharma's financing, expanding their rare disease portfolio focus. Novartis Venture Fund's investment in Rhygaze reflects their ophthalmology franchise and gene therapy capabilities through Luxturna's development experience.

These strategic investments often include collaboration agreements, regulatory expertise sharing, and potential acquisition pathways, providing startups with validation beyond capital. NVIDIA Ventures' participation in ArsenalBio signals computing infrastructure importance for complex cell engineering platforms.

If you want to build or invest on this market, you can download our latest market pitch deck here

Which investment rounds had the highest valuations and what do they signal?

ArsenalBio's $325 million Series C likely reflects a valuation exceeding $1 billion based on the investor syndicate quality and pipeline advancement stage.

Capstan Therapeutics' $175 million oversubscribed Series B suggests strong valuation momentum driven by their in vivo delivery platform's potential to transform manufacturing economics. The participation of multiple Big Pharma companies indicates competitive valuation dynamics.

Neurona Therapeutics' $102 million private round at Phase 3 stage with RMAT designation commands premium pricing given reduced regulatory risk and accelerated approval pathway. Their allogeneic approach addresses manufacturing scalability that typically constrains autologous therapies.

Umoja Biopharma's $100 million Series C supports multiple platform programs, suggesting efficient capital deployment across a broad therapeutic pipeline. The universal donor approach potentially unlocks massive market opportunities justifying higher valuations.

These valuations reflect investor confidence in platform technologies that can address multiple indications, reduce manufacturing complexity, and overcome traditional cell therapy limitations. Companies with clear paths to commercial scalability command premium valuations regardless of early-stage clinical data.

Planning your next move in this new space? Start with a clean visual breakdown of market size, models, and momentum.

What types of investors are most active in cell therapy funding?

Specialized healthcare venture capital firms dominate cell therapy investments, with ARCH Venture Partners, RA Capital Management, and DCVC Bio leading multiple rounds.

• Venture Capital Firms: ARCH Venture (ArsenalBio, Be Biopharma), RA Capital (Capstan, Umoja), Double Point Ventures (Umoja), Atlas Venture (Be Biopharma)
• Corporate Venture Arms: Johnson & Johnson Innovation, Bristol Myers Squibb Ventures, Regeneron Ventures, Novartis Venture Fund, Takeda Ventures
• Crossover Funds: Fidelity, Viking Global, Soleus Capital providing later-stage growth capital
• Technology Investors: Google Ventures (Rhygaze), NVIDIA Ventures (ArsenalBio), SoftBank Vision Fund 2 (ArsenalBio)
• Family Offices: The Column Group participating in premium rounds

Corporate venture arms provide strategic value beyond capital through regulatory expertise, commercialization pathways, and potential acquisition routes. Technology sector investors bring platform thinking and scalability focus that complements traditional biotech investment approaches.

Are any platform technologies or manufacturing innovations receiving significant investment?

Manufacturing and platform technologies captured substantial investment through companies developing scalable, cost-effective production methods.

Capstan Therapeutics' $175 million financing directly targets manufacturing innovation through their in vivo delivery platform that eliminates complex ex vivo cell processing. This approach could reduce treatment costs from hundreds of thousands to tens of thousands of dollars per patient.

Umoja Biopharma's $100 million round supports universal donor platforms that bypass patient-specific manufacturing entirely. Their VivoVec in vivo delivery system and TumorTag allogeneic CAR-T platforms address the two major manufacturing bottlenecks: complex processing and patient-specific production.

ArsenalBio's CITE platform includes manufacturing optimization through their programmable logic gates that enhance CAR-T specificity and reduce off-target effects. This reduces manufacturing failure rates and improves product consistency.

A2 Biotherapeutics' Tmod platform enables more predictable manufacturing outcomes through their dual-receptor safety switches. Platform approaches that enable multiple therapeutic applications from a single manufacturing infrastructure consistently attract larger investment rounds than single-indication companies.

Wondering who's shaping this fast-moving industry? Our slides map out the top players and challengers in seconds.

If you need to-the-point data on this market, you can download our latest market pitch deck here

Which emerging companies could potentially disrupt the established cell therapy market?

Capstan Therapeutics represents the most significant potential disruptor with their in vivo CAR-T technology that could eliminate traditional manufacturing constraints entirely.

Rhygaze brings optogenetic approaches to cell therapy, expanding applications beyond oncology into ophthalmology and potentially other sensory restoration applications. Their $86 million Series A with Google Ventures backing signals strong commercial potential in underserved markets.

Neurona Therapeutics pioneers CNS applications with their allogeneic interneuron transplants, opening entirely new therapeutic territories for cell therapy. Their Phase 3 EPIC trial for drug-resistant epilepsy could validate cell therapy efficacy in neurological disorders.

Be Biopharma's B-cell engineering platforms expand beyond traditional T-cell approaches, potentially accessing autoimmune and rare disease markets with different regulatory pathways and commercial dynamics. Their hemophilia and hypophosphatasia programs target well-defined patient populations with quantifiable endpoints.

A2 Biotherapeutics' Tmod dual-receptor system could solve the safety challenges that have limited CAR-T expansion into solid tumors, potentially unlocking the largest oncology markets that remain inaccessible to current cell therapies.

How much total funding flowed into cell therapy in 2024-2025?

The cell therapy sector attracted over $1.3 billion in disclosed funding across major startups between 2024 and mid-2025, representing continued strong investor interest despite broader biotech funding challenges.

Industry reports indicate that cell and gene therapy investment reached $10.9 billion in H1 2024 alone, exceeding 2019's full-year total and demonstrating sector resilience. The total 2024 cell and gene therapy investment reached $15.2 billion, representing a 30% year-over-year increase despite broader market headwinds.

Q1 2025 seed and Series A funding totaled $304.3 million across the sector, showing a 20% volume decrease and 50% value decrease compared to Q1 2024. However, later-stage rounds remained robust, with the largest financings concentrated in clinical-stage companies with validated platforms.

The funding concentration in larger rounds suggests investor preference for established companies with clear regulatory pathways rather than early-stage ventures. This trend indicates market maturation where investors demand stronger scientific validation and clearer commercial pathways.

Cross-border investment remained strong, with European and Asian investors participating in US-based rounds, while US investors backed international companies, demonstrating the global nature of cell therapy innovation and capital flows.

What investment trends do experts predict for cell therapy in 2026?

Industry experts predict a continued shift toward commercial-stage companies with human clinical data and clear regulatory pathways, following the pattern established in 2024-2025 funding rounds.

Platform technologies and manufacturing innovations will attract increasing investment as investors prioritize scalable solutions over single-indication approaches. Companies demonstrating cost-of-goods-sold improvements and manufacturing efficiency gains will command premium valuations.

Pharma-sponsored collaborations and strategic partnerships will grow significantly, with corporate venture arms leading larger rounds and providing validation for emerging technologies. The success of J&J Innovation, BMS Ventures, and Regeneron Ventures in 2024-2025 rounds establishes this trend.

Geographic expansion beyond traditional US biotech hubs will accelerate, with increased activity in European and Asia-Pacific ecosystems supported by government funding initiatives and regional expertise centers. Cross-border collaboration will become standard for platform companies seeking global market access.

Intellectual property consolidation through mergers, acquisitions, and licensing deals will intensify as larger companies integrate novel platforms like CRISPR/Cas systems into their existing infrastructure. Companies with broad platform applications will become acquisition targets for established cell therapy leaders.

Need a clear, elegant overview of a market? Browse our structured slide decks for a quick, visual deep dive.

Conclusion

Sources

1. BioPharma Dive - Capstan Series B
2. Forbion - Capstan Investment
3. Fierce Biotech - Neurona Funding
4. Pharmaceutical Technology - Neurona Raises 102M
5. Fierce Biotech - ArsenalBio Funding
6. Pharmaceutical Technology - Capstan CAR-T
7. Alliance for Regenerative Medicine - Q1 2025 Report
8. BioSpace - Cell and Gene Therapy Investment
9. BioSpace - 30% Investment Surge
10. ASGCT - Q1 2025 Report
11. ArsenalBio - $325M Financing Announcement
12. Neurona Therapeutics - Press Release